Amaxa and Promega are working together to provide broader access to monitor cell-signaling events in difficult-to-transfect cells including stem cells, cancer cells, and primary cells. Integrating their tools in luminescence-based assays and transfection methodologies will simplify transfection of reporter genes and assay development in these cell types, according to the companies.
Amaxa’s Nucleofector® technology is used for transfection in applications involving more biologically relevant mammalian systems such as primary cells and stem cells. “With the Nucleofector technology, transfection efficiencies of up to 95% using DNA and 99% using siRNA oligonucleotides can be achieved in difficult-to-transfect cells,” states Rainer Christine, co-founder and CEO, Amaxa. “Thus, the combination of Promega and Amaxa technologies will enable researchers to obtain much more significant results with physiologically relevant cells rather than more artificial cell lines.”
Promega says that its luciferase reporter gene vectors and assay reagents are sensitive bioluminescent tools to monitor cell signaling events and provide the dynamic range in reporter assay technologies. “Luciferase reporters are routinely used to monitor gene expression and are ideal tools for high-throughput screening, RNAi-mediated gene regulation, and detection of cellular metabolism and viability,” explains John Watson, director of cellular analysis, Promega. “The combination of Promega’s luciferase products and Amaxa’s technology will enable the generation of stable cell lines and bioluminescent cell-based assays even for primary cells.”